Results from the phase 3 EPCORE DLBCL-1 clinical trial show that patients with relapsed or refractory diffuse large B-cell ...
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...
Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) ...
Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...
Researchers noted that despite the promising findings, more novel treatments are needed to overcome the disease’s resistance. Patients with penta-relapsed refractory multiple myeloma (RRMM) exhibited ...
13don MSN
Expert guidance urges caution before surgery for patients with treatment-resistant constipation
A new update from the American Gastroenterological Association (AGA) is calling for greater caution before surgery is ...
A new clinical practice update outlines a stepwise approach to diagnosing and managing refractory constipation before ...
Surgery for refractory constipation should be a last resort, used only after comprehensive physiologic and psychological ...
Chronic constipation affects 8–12% of Americans. While most patients improve with conventional treatments, a small but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback